Letrozolum Genthon

Letrozole, the active ingredient in Letrozolum Genthon, is an aromatase inhibitor presented as an oral tablet for systemic use. It reduces estrogen production and is employed in the treatment of estrogen receptor‑positive breast cancer in postmenopausal women, including adjuvant and metastatic settings.

GNH USA supplies Letrozolum Genthon as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The product complies with EU quality standards and is intended for use under medical supervision. It is distributed to hospitals, pharmacies and specialized cancer treatment facilities across multiple continents.

Letrozole is employed in hormone‑dependent breast cancer therapy, targeting estrogen‑driven disease processes. - Estrogen receptor‑positive breast cancer in postmenopausal women: Reduces tumor growth by lowering circulating estrogen levels. - Adjuvant treatment of early breast cancer: Decreases risk of disease recurrence after surgery when used as part of endocrine therapy. - Metastatic breast cancer: Helps control disease progression in advanced stages by maintaining low estrogen environment. - Hormone receptor‑positive breast cancer (any stage): Provides systemic estrogen suppression to improve survival outcomes when combined with other agents.

Letrozole may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Hot flashes: Sudden feeling of warmth, sweating, and flushing that may disrupt daily activities. - Joint and muscle pain: Arthralgia and myalgia that can limit mobility and cause discomfort. - Fatigue: Persistent tiredness affecting physical and mental performance. - Nausea: Mild gastrointestinal upset that may be transient. - Headache: Persistent head pain that can vary in intensity. - Insomnia: Difficulty falling or staying asleep, leading to reduced rest.

Serious or Rare Side Effects: - Osteoporosis or bone fractures: Decreased bone mineral density increasing risk of fractures, especially in long‑term use. - Severe liver dysfunction: Elevated transaminases, hepatitis, or hepatic failure requiring monitoring. - Cardiovascular events: Thromboembolic disorders, stroke, or myocardial infarction may occur rarely. - Allergic reactions: Rash, angioedema, or anaphylaxis demanding immediate medical attention.

When prescribing Letrozole, clinicians should consider several safety precautions to minimize risk. - Assess bone health: Baseline DEXA scan recommended because letrozole can accelerate bone loss. - Monitor liver function: Periodic liver enzyme tests to detect potential hepatotoxicity. - Evaluate cardiovascular risk: Use caution in patients with prior thromboembolic events. - Avoid use in pregnancy: Contraindicated due to teratogenic risk; pregnancy category X. - Review concomitant medications: Check for drugs that may alter estrogen levels or CYP activity. - Store at ambient temperature: Keep below 25°C in original packaging, protect from moisture.

Letrozole can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): May reduce letrozole plasma concentrations and diminish therapeutic effect. - Estrogen‑containing therapies (hormone replacement, oral contraceptives): Counteract estrogen suppression, potentially decreasing efficacy.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., fluconazole): May increase letrozole levels, requiring observation for toxicity. - Warfarin: Potential alteration of anticoagulant effect; monitor INR closely. - Tamoxifen: Combined endocrine therapy may affect outcomes; clinical judgment required. - SSRIs (e.g., fluoxetine, paroxetine): May inhibit CYP enzymes affecting letrozole metabolism; monitor for increased adverse effects.